Molecular Biomedicine is a peer-reviewed, online open access, multidisciplinary journal that publishes the pioneer works of biomedicine, emphasizing on pathogenic mechanism and innovative techniques for diagnosis and therapy. The journal editorial office (email@example.com) is dedicated to providing professional and responsive service for authors.
The journal covers topics including but not limited to genetics/epigenetics, molecular biology, cell biology, bioinformatics, pharmacology, pharmacy, and clinical medicine. Molecular Biomedicine publishes a range of content types, including original research article, review, letter to the editor and research highlight, offering the latest advances in basic, translational and clinical research to meet the needs of academic readers in this field.
- Arnold Driessen,
- Yu-quan Wei
- Publishing model
- Open Access. Learn about publishing OA with us
Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy
Authors (first, second and last of 11)
Authors (first, second and last of 4)
All articles published by the Molecular Biomedicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers.
If you have queries about presubmission enquiries,submission issues, peer review process, or the status of your manuscript, please contact the editorial office: firstname.lastname@example.org.
Molecular Biomedicine is affiliated with Sichuan International Medical Exchange & Promotion Association (SCIMEA), sponsored by Chengdu BIOMEDICAL International Biomedicine Scientific Information Institute Company Limited , a registered company of which SCIMEA is the sole shareholder.